Cat. No.: HY-B1334

Perhexiline

6 Cited Publications

Customer Review

Based on 6 publication(s) in Google Scholar

Perhexiline is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline can be used in the research of cancers, and cardiovascular disease like angina.

For research use only. We do not sell to patients.

Purity: 99.96%
CAS No.: 6621-47-2
Formula: C₁₉H₃₅N
Molecular Weight:277.49

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Perhexiline Chemical Structure

CAS No.: 6621-47-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (6)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

CPT-1

CPT-2

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	IC₅₀	11.3 μM Compound: Perhexiline	Cytotoxicity against human HepG2 cells assessed as growth inhibition by XTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition by XTT assay	[PMID: 36793433]
KB	IC₅₀	14.8 μM Compound: 44	Cytotoxicity in human KB cells Cytotoxicity in human KB cells	[PMID: 21504156]
Vero	CC₅₀	8.67 μM Compound: Perhexiline	Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr	10.1101/2020.03.20.999730
Vero	IC₅₀	6.38 μM Compound: Perhexiline	Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr	10.1101/2020.03.20.999730

In Vitro

Perhexiline (5-25 μM, 2-6 h) reduces cell viability in HepG2 cells^[2].
Perhexiline (5-25 μM, 2-6 h) reduces cellular ATP content and Lactate dehydrogenase (LDH) release in HepG2 cells^[2].
Perhexiline (20 μM, 2 h) activates caspase 3/7 in HepG2 cells^[2].
Perhexiline (5-25 μM, 4 h) causes mitochondrial dysfunction in HepG2 cells^[2].
Perhexiline (5 μM, 48 h) selectively induces massive apoptosis in CLL cells (high expression of CPT)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

HepG2 cells
Concentration:

5, 10, 15, 25 μM
Incubation Time:

2, 4, 6 h
Result:

Induced time- and concentration-dependent cytotoxicity in hepatic cells.

Western Blot Analysis^[2]

Cell Line:

HepG2 cells
Concentration:

5, 10, 15, 25 μM
Incubation Time:

2 h
Result:

Reduced Bcl-2 and Mcl-1 level, and increased Bad level.

In Vivo

Perhexiline (200 mg/kg, p.o., daily for 8 weeks) reduces peripheral neural function in female DA rats^[4].
Perhexiline (80 mg/kg, oral gavage, for 3 days) demonstrates anti-tumor activity in glioblastoma mouse model^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Orthotopic glioblastoma mouse model^[5]
Dosage:

80 mg/kg
Administration:

Oral gavage, for 3 days.
Result:

Reduces tumor size (MR imaging) and improves in overall survival.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 6621-47-2
Appearance Solid
Molecular Weight 277.49
Formula C₁₉H₃₅N
Color White to off-white
SMILES

C1(CC(C2CCCCC2)C3CCCCC3)NCCCC1
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (6)

All Histological Imaging/StainingCell Imaging/StainingBio/Physico-chemical AssayWBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Nat Genet

Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma. [Abstract]

2025 Mar;57(3):680-693. PMID: 40069506

Perhexiline purchased from MedChemExpress. Usage Cited in: Nat Genet. 2025 Mar;57(3):680-693. [Abstract]

Inhibition of CPT1A activity using Perhexiline maleate (0-10 μM, 24 h) and PD-L1 detection by western blotting in A375 cell.

Perhexiline purchased from MedChemExpress. Usage Cited in: Nat Genet. 2025 Mar;57(3):680-693. [Abstract]

A375 cells treated with Perhexiline maleate (0-10 μM) for 24 h, then co-cultured with or without activated T cells for 24 h to assess the killing effect.
Acta Pharm Sin B

GSFM: A genome-scale functional module transformation to represent drug efficacy for in silico drug discovery. [Abstract]

2025 Jan;15(1):133-150. PMID: 40041913

Perhexiline purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Jan;15(1):133-150. [Abstract]

Results of H&E and Ki67 staining in representative A549 cells tumor sections of vehicle, perhexiline (10 mg/kg, ip, 3 days), and Perhexiline maleate (10 mg/kg) treated naked mice. Scale bar = 200 μm (H&E up).

Perhexiline purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Jan;15(1):133-150. [Abstract]

Perhexiline maleate (0-20 μM, 8 days) exhibited inhibition of colony formation in A549 and NCI-H1975 cells.

Perhexiline purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Jan;15(1):133-150. [Abstract]

Reversal relationship between LUAD GSFM pattern and Perhexiline maleate GSFM pattern.
Adv Sci (Weinh)

Loss of OVOL2 in Triple-Negative Breast Cancer Promotes Fatty Acid Oxidation Fueling Stemness Characteristics. [Abstract]

2024 Apr 16:e2308945. PMID: 38627980
Cancer Metab

Unveiling the powerhouse: ASCL1-driven small cell lung cancer is characterized by higher numbers of mitochondria and enhanced oxidative phosphorylation. [Abstract]

2025 Mar 31;13(1):16. PMID: 40165271
BMC Biol

Targeting of REST with rationally-designed small molecule compounds exhibits synergetic therapeutic potential in human glioblastoma cells. [Abstract]

2024 Apr 12;22(1):83. PMID: 38609948
Pestic Biochem Physiol

2025 Dec 22;218:106908.

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (360.37 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.6037 mL

18.0187 mL

36.0373 mL

5 mM

0.7207 mL

3.6037 mL

7.2075 mL

10 mM

0.3604 mL

1.8019 mL

3.6037 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. E. Marc Jolicoeur, et al. 27 - Refractory Angina. Chronic Coronary Artery Disease, 2018, 412-431.

[2]. Zhen Ren, et al. Mitochondrial dysfunction and apoptosis underlie the hepatotoxicity of perhexiline. Toxicol In Vitro. 2020 Dec;69:104987. [Content Brief]

[3]. P-P Liu, et al. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline. Oncogene. 2016 Oct 27;35(43):5663-5673. [Content Brief]

[4]. Giovanni Licari, et al. Enantioselectivity in the tissue distribution of perhexiline contributes to different effects on hepatic histology and peripheral neural function in rats. Pharmacol Res Perspect. 2018 Jun;6(3):e00406. [Content Brief]

[5]. Shiva Kant, et al. Perhexiline Demonstrates FYN-mediated Antitumor Activity in Glioblastoma. Mol Cancer Ther. 2020 Jul;19(7):1415-1422. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.6037 mL	18.0187 mL	36.0373 mL	90.0933 mL
	5 mM	0.7207 mL	3.6037 mL	7.2075 mL	18.0187 mL
	10 mM	0.3604 mL	1.8019 mL	3.6037 mL	9.0093 mL
	15 mM	0.2402 mL	1.2012 mL	2.4025 mL	6.0062 mL
	20 mM	0.1802 mL	0.9009 mL	1.8019 mL	4.5047 mL
	25 mM	0.1441 mL	0.7207 mL	1.4415 mL	3.6037 mL
	30 mM	0.1201 mL	0.6006 mL	1.2012 mL	3.0031 mL
	40 mM	0.0901 mL	0.4505 mL	0.9009 mL	2.2523 mL
	50 mM	0.0721 mL	0.3604 mL	0.7207 mL	1.8019 mL
	60 mM	0.0601 mL	0.3003 mL	0.6006 mL	1.5016 mL
	80 mM	0.0450 mL	0.2252 mL	0.4505 mL	1.1262 mL
	100 mM	0.0360 mL	0.1802 mL	0.3604 mL	0.9009 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Perhexiline

Apoptosis Compound Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Cancer Metabolism Compound Library

Mitochondria-Targeted Compound Library

Glucose Metabolism Compound Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Cuproptosis Compound Library

Heterocyclic Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Mitochondrial Toxicity Compound Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Perhexiline

Biological Activity

Chemical Information

Publications (6)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Perhexiline Related Classifications

Cat. No.: HY-B1334